PURE Pharmaceuticals builds a high-end formulation CDMO service platform

Leveraging its deep expertise in active pharmaceutical ingredients (APIs), Henan Pury Pharmaceutical Co., Ltd. has achieved remarkable success in extending its reach downstream into formulation manufacturing. The company has established modern production lines covering various dosage forms, including small-volume injections (including BFS process and glass ampoules), inhalation solutions, eye drops, tablets, capsules, granules, and dry suspensions. Among these, the BFS (blow-fill-seal) production line utilizes internationally advanced aseptic technology, enabling automated continuous production of small-volume injections and significantly improving aseptic quality and production efficiency.

Purui Pharmaceutical's formulation products are widely used in clinical fields such as internal medicine, surgery, pediatrics, ophthalmology, and respiratory medicine. Capitalizing on its unique advantages in anticholinergic and emergency APIs, the company has developed a series of high-end formulations with clinical value and simultaneously undertakes formulation CDMO (contract development and manufacturing organization) business for global clients. Services encompass pre-formulation research, process scale-up, clinical sample production, commercial production, and registration support, providing partners with a full-cycle solution from project initiation to market launch.

In recent years, PURUI Pharmaceuticals has obtained national GMP certification and been awarded the title of "National High-tech Enterprise." Its formulation production lines strictly adhere to domestic and international quality standards. The company's quality testing center is equipped with high-precision analytical instruments such as liquid chromatography to conduct comprehensive testing on raw materials, intermediates, semi-finished products, and finished products used in formulation production, ensuring the safety, efficacy, and stability of each batch.

"Formulations are the final form of medicines presented to patients and represent the ultimate embodiment of our entire industry chain value," noted the head of PURE Pharmaceuticals' formulation business unit. "In the future, we will further expand into high-barrier dosage forms such as inhaled and ophthalmic formulations, and improve the response speed and flexibility of our CDMO services to help our global partners accelerate the launch of new drugs."